SELLAS Vaccine More Than Doubles Time to Myeloma Progression, Phase 2 Trial Shows
SELLAS Life Sciences’  Galinpepimut-S vaccine more than doubles the time it takes for high-risk multiple myeloma patients’ cancer to worsen, a Phase 2 clinical trial shows.